DR.Noah Biotech

Established in 2017, DR.NOAH BIOTECH Inc. is a cutting-edge biotech dedicated to develop New Drug Combinations (NDCs) by utilizing AI technology. With our unrivaled AI technology, we are developing treatments for rare neurological/neuromuscular disorders. There are over seven thousand rare diseases and many neurological disorders. Although it is called “rare”, the actual number of rare disease patient is large. About 5% of the global population live with a rare disease, and 95% of rare diseases lack an FDA-approved treatment. So, we decided to design New Drug Combinations (NDCs) to speed the delivery of new treatments. Our development strategy is simple and clear. We are designing NDCs using existing drugs that target Multifactorial Mechanisms. And this strategy not only maximize the therapeutic effects but also has the advantages of reducing the early development time and costs. Our AI platform called ARK is an unparalleled platform capable of addressing a wide range of tasks, including early new drug combination prediction, cellular phenotype-based drug efficacy evaluation and prediction of clinical DDI (Drug-Drug Interaction) risk. Our main pipelines developed using the ARK platform 1) NDC-002 (Stroke Recovery): The very first AI-driven drug that approved for clinical trial in Korea. Clinical Trial Phase 1 was successfully completed last year, and safety was confirmed. 2) NDC-011 (ALS): Orphan Drug Designation (ODD) by the U.S. FDA (September 2023) 3) NDC-026 (DMD): Rare pediatric Diseases Designation (RPDD) and an Orphan Drug Designation (ODD) by the U.S. FDA (April 2024)